ORIC Pharmaceuticals, Inc. (ORIC)
US — Healthcare Sector
Automate Your Wheel Strategy on ORIC
With Tiblio's Option Bot, you can configure your own wheel strategy including ORIC - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ORIC
- Rev/Share 0.0075
- Book/Share 3.0931
- PB 2.6413
- Debt/Equity 0.0
- CurrentRatio 12.0016
- ROIC -0.651
- MktCap 580789777.0
- FreeCF/Share -1.6326
- PFCF -5.0077
- PE -4.3686
- Debt/Assets 0.0
- DivYield 0
- ROE -0.5114
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 3
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | ORIC | Stifel | -- | Buy | -- | $20 | Sept. 6, 2024 |
News
Wall Street Analysts Predict a 131.33% Upside in Oric Pharmaceuticals (ORIC): Here's What You Should Know
ORIC
Published: June 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Published: June 02, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 131.3% upside potential for Oric Pharmaceuticals (ORIC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
ORIC Stock Surges on Upbeat Initial Data From Prostate Cancer Study
ORIC
Published: May 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Published: May 29, 2025 by: Zacks Investment Research
Sentiment: Positive
ORIC Pharmaceuticals stock rises 20% pre-market on early data showing strong PSA responses and tolerability for prostate cancer drug ORIC-944 in phase Ib study.
Read More
About ORIC Pharmaceuticals, Inc. (ORIC)
- IPO Date 2020-04-24
- Website https://www.oricpharma.com
- Industry Biotechnology
- CEO Dr. Jacob M. Chacko M.B.A., M.D.
- Employees 122
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.